Promising combo therapy shows hope for Hard-to-Treat bile duct cancer
NCT ID NCT07466238
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a treatment strategy for biliary tract cancer, a group of aggressive cancers with poor survival. The approach combines hepatic arterial infusion chemotherapy (HAIC) with systemic drugs like bevacizumab and an immunotherapy. The goal is to shrink tumors and improve survival, possibly allowing some patients to have surgery. The trial enrolls 40 patients who have not received prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- gemcitabine, oxaliplatin, 5-fluorouracil, bevacizumab, PD-1/PD-L1 inhibitor
- What this could lead to
- If successful, this approach could offer a more effective first-line treatment for advanced biliary tract cancer, potentially shrinking tumors enough to allow surgery and extend survival.
- What could go wrong
- This is a small, early-phase study with no control group, so results may not be generalizable. The combination therapy also carries risks of side effects from chemotherapy and immunotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER (BTC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, 100142, China
-
Peking University Cancer Hospital
NOT_YET_RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Can matching cancer drugs to tumor genes prevent biliary tract cancer return?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can a dual immune booster plus chemo shrink hard-to-treat bile duct tumors?